Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma

Onkologie

Volumn 27, Issue 6, 2004, Pages 540-544

  Fink, W ^a   Zimpfer Rechner, C ^a   Thoelke, A ^a   Figl, R ^a   Kaatz, M ^b   Ugurel, S ^a   Schadendorf, D ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Doxorubicin, pegylated liposomal; Melanoma; Second line treatment; Survival

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; PYRIDOXINE;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MALE; MELANOMA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; RESPIRATORY FAILURE; SKIN MANIFESTATION; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERMANY; HEMATOLOGIC DISEASES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PALLIATIVE CARE; POLYETHYLENE GLYCOLS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 10844220559     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081335     Document Type: Article

References (19)

1. Lens MB, Dawes M: Interferon alfa therapy for malignant melanoma: A systematic review of randomized controlled trials. J Clin Oncol 2002;20: 1818-1825.
2. Stadelmann WK, Rapaport DP, Soong SJ, Reintgen DS, Buzaid AC, Balch CM: Prognostic clinical and pathological features; in Balch CM, Houghton AN, Sober AJ, Soong SJ (eds): Cutaneous Melanoma. St. Louis, MO, Berger, 1998, pp 11-36.
3. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN: Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993;72:3091-3098.
4. Schadendorf D: Is there a standard for the palliative treatment of melanoma? Onkologie 2002;25:74-76.
5. Lee ML, Tomsu K, von Eschen KB: Duration of survival for disseminated malignant melanoma: Results of a meta-analysis. Melanoma Res 2000;10: 81-92.
6. Hortobagyi GN: Anthracyclines in the treatment of cancer. An overview. Drugs 1997;54(Suppl 4):1-7.
7. Stewart S, Jablonowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 1998;16:683-691.
8. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001;19:3312-3322.
9. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13:1777-1785.
10. Alberts DS, Garcia DJ: Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997;54(Suppl 4):30-35.
11. Schadendorf D, Worm M, Algermissen B, Kohlmus CM, Czarnetzki BM: Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity. Cancer 1994;73:103-108.
12. Vukelja SJ, Baker WJ, Burris HA 3rd, Keeling JH, Von Hoff D: Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993;85:1432-1433.
13. Vukelja SJ, Lombardo FA, James WD, Weiss RB: Pyridoxine for the palmarplantar erythrodysesthesia syndrome. Ann Intern Med 1989;111:688-689.
14. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE: Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998;4:1567-1571.
15. Wollina U, Graefe T, Kaatz M: Pegylated doxorubicin for primary cutaneous Tcell lymphoma: A report on ten patients with follow-up. J Cancer Res Clin Oncol 2001;127:128-134.
16. Lotem M, Hubert A, Lyass O, Goldenhersh MA, Ingber A, Peretz T, Gabizon A: Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000;136:1475-1480.
17. Baas P, van Meerbeeck J, Groen H, Schouwink H, Burgers S, Daamen S, Giaccone G: Caelyx in malignant mesothelioma: A phase II EORTC study. Ann Oncol 2000;11:697-700.
18. Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS: Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy. Oncol Rep 1999;6:1097-1099.
19. Vorobiof DA, Rapoport BL, Mahomed R, Karime M: Phase II study of pegylated liposomal doxorubicin in patients with metastatic malignant melanoma failing standard chemotherapy treatment. Melanoma Res 2003;13:201-203.